Positive high-level results from the POTOMAC phase III trial showed one year of treatment with AstraZeneca’s Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy ...

AstraZeneca aims to widen the pool of bladder ... In the company’s POTOMAC phase 3 study, patients with high-risk NMIBC who were treated with Imfinzi for one year—along with standard-of ...

New Delhi: UK pharma major AstraZeneca in partnership with health ... including lung nodules at high risk for cancer in nearly 50,000 people who were later referred for further testing and ...

Campfire Audio, known for its high-end in-ear monitors ... outfitting them with USB-C connectivity, a built-in hi-res DAC, and a shiny new contemporary styling, all for $249.

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN ...

A satellite the size of a suitcase sent back these 2.5-meter resolution photos of the Earth’s surface. A satellite the size of a suitcase sent back these 2.5-meter resolution photos of the Earth ...

AstraZeneca PLC (NASDAQ:AZN) 52 Week Range: $60.47 – $87.55 Current Share Price: $87.45 Short interest rate: 0.27% Number of Hedge Fund Holders: 49 Headquartered in Cambridge, the United Kingdom ...

We recently compiled a list of the 14 Best 52-Week High Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the ...

AstraZeneca ADRs rose to a record high Tuesday following the announcement. AstraZeneca's (AZN) American depositary receipts (ADRs) rose over 2% to a record high Tuesday after the Anglo-Swedish ...

London's FTSE on Wednesday 100 stock index soared to unprecedented levels, buoyed by AstraZeneca's strong performance. The pharmaceutical company's global decision to halt its COVID-19 vaccine ...

Cambridge-based AstraZeneca, which is contesting the claims, acknowledged in a legal document submitted to the High Court in February that its vaccine 'can, in very rare cases, cause TTS'.

AstraZeneca and Daiichi Sankyo's Enhertu showed positive high-level results of improvement in PFS compared to standard-of-care chemotherapy in the primary trial population of patients. Enhertu is ...